Evidence map›Paper›PMID 38613168›Full record

ArticleAmerican journal of medical genetics. Part A2024

Immunological and hematological findings as major features in a patient with a new germline pathogenic CBL variant.

Emilia Stellacci, Jennefer N Carter, Luca Pannone, David Stevenson, Dorsa Moslehi, Serenella Venanzi, Undiagnosed Diseases Network, Jonathan A Bernstein, Marco Tartaglia, Simone Martinelli

Open access · hybridAbstract readCase Reports
In one paragraph

Article in American journal of medical genetics. Part A, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Emilia StellacciDepartment of Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.
Jennefer N CarterStanford Center for Undiagnosed Diseases, Stanford University, Stanford, California, USA.
Luca PannoneMolecular Genetics and Functional Genomics Research Unit, Ospedale Pediatrico Bambino Gesù, IRCCS, Rome, Italy.
David StevensonStanford Center for Undiagnosed Diseases, Stanford University, Stanford, California, USA.ORCID 0000-0001-8601-0020
Dorsa MoslehiStanford Center for Undiagnosed Diseases, Stanford University, Stanford, California, USA.
Serenella VenanziDepartment of Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.
Undiagnosed Diseases Network
Jonathan A BernsteinStanford Center for Undiagnosed Diseases, Stanford University, Stanford, California, USA.ORCID 0000-0001-5369-346X
Marco TartagliaMolecular Genetics and Functional Genomics Research Unit, Ospedale Pediatrico Bambino Gesù, IRCCS, Rome, Italy.ORCID 0000-0001-7736-9672
Simone MartinelliDepartment of Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.ORCID 0000-0002-5843-419X
Istituto Superiore di Sanità · ITStanford University · USBambino Gesù Children's Hospital · IT

Funding

What comes next? Engaging stakeholders in governance of participant data and relationships during the sunset of large genomic medicine research initiativesU01HG010218 · NHGRI · STANFORD UNIVERSITY · PI ASHLEY, EUAN A, BERNSTEIN, JONATHAN ADAM · 2018 to 2022
$6.3M
Center for Undiagnosed Diseases at StanfordU01NS134358 · NINDS · STANFORD UNIVERSITY · PI Jonathan Adam Bernstein, HOLLY K TABOR · 2023 to 2026
$3.1M
UCLA clinical site for the investigation of undiagnosed disordersU01NS134356 · NINDS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI MARTINEZ-AGOSTO, JULIAN, NELSON, STANLEY F. · 2023 to 2023
$936k
Associazione Italiana per la Ricerca sul Cancro, AIRC IG 28768European Joint Programme on Rare Diseases, EJP-RD: NSEuroNetItalian Ministry of HealthNHGRI NIH HHS U01 HG010218NIH Common Fund U01HG010218NINDS NIH HHS U01 NS134356NINDS NIH HHS U01 NS134358
6 · The paper itself

Abstract

Casitas B-lineage lymphoma (CBL) encodes an adaptor protein with E3-ligase activity negatively controlling intracellular signaling downstream of receptor tyrosine kinases. Somatic CBL mutations play a driver role in a variety of cancers, particularly myeloid malignancies, whereas germline defects in the same gene underlie a RASopathy having clinical overlap with Noonan syndrome (NS) and predisposing to juvenile myelomonocytic leukemia and vasculitis. Other features of the disorder include cardiac defects, postnatal growth delay, cryptorchidism, facial dysmorphisms, and predisposition to develop autoimmune disorders. Here we report a novel CBL variant (c.1202G>T; p.Cys401Phe) occurring de novo in a subject with café-au-lait macules, feeding difficulties, mild dysmorphic features, psychomotor delay, autism spectrum disorder, thrombocytopenia, hepatosplenomegaly, and recurrent hypertransaminasemia. The identified variant affects an evolutionarily conserved residue located in the RING finger domain, a known mutational hot spot of both germline and somatic mutations. Functional studies documented enhanced EGF-induced ERK phosphorylation in transiently transfected COS1 cells. The present findings further support the association of pathogenic CBL variants with immunological and hematological manifestations in the context of a presentation with only minor findings reminiscent of NS or a clinically related RASopathy.

Indexed as

Germ-Line MutationProto-Oncogene Proteins c-cblAnimalsAutism Spectrum DisorderChildChild, PreschoolCOS CellsGenetic Predisposition to DiseaseHumansMaleNoonan SyndromePhenotypeThrombocytopeniaCBL protein, humanProto-Oncogene Proteins c-cblCBLCBL syndromeNoonan syndromephenotypic spectrumRAS signaling

Identifiers

PMID38613168
PMCPMC11223960
OpenAlexW4394785575

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.